Gamma protocadherins in vascular endothelial cells inhibit Klf2/4 to promote atherosclerosis.
Divyesh JoshiBrian G CoonRaja ChakrabortyHanqiang DengPablo Fernandez-TussyEmily MeredithJames G TraylorAnthony Wayne OrrCarlos Fernandez-HernandoMartin A SchwartzPublished in: bioRxiv : the preprint server for biology (2024)
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide 1 . Laminar shear stress (LSS) from blood flow in straight regions of arteries protects against ASCVD by upregulating the Klf2/4 anti-inflammatory program in endothelial cells (ECs) 2-8 . Conversely, disturbed shear stress (DSS) at curves or branches predisposes these regions to plaque formation 9,10 . We previously reported a whole genome CRISPR knockout screen 11 that identified novel inducers of Klf2/4. Here we report suppressors of Klf2/4 and characterize one candidate, protocadherin gamma A9 (Pcdhga9), a member of the clustered protocadherin gene family 12 . Pcdhg deletion increases Klf2/4 levels in vitro and in vivo and suppresses inflammatory activation of ECs. Pcdhg suppresses Klf2/4 by inhibiting the Notch pathway via physical interaction of cleaved Notch1 intracellular domain (NICD Val1744) with nuclear Pcdhg C-terminal constant domain (CCD). Pcdhg inhibition by EC knockout (KO) or blocking antibody protects from atherosclerosis. Pcdhg is elevated in the arteries of human atherosclerosis. This study identifies a novel fundamental mechanism of EC resilience and therapeutic target for treating inflammatory vascular disease.
Keyphrases
- endothelial cells
- cardiovascular disease
- blood flow
- transcription factor
- signaling pathway
- anti inflammatory
- genome wide
- cell proliferation
- oxidative stress
- cardiovascular events
- crispr cas
- mental health
- type diabetes
- physical activity
- risk factors
- genome editing
- metabolic syndrome
- climate change
- quality improvement
- depressive symptoms
- gene expression
- induced pluripotent stem cells